Keros Accounts Payable from 2010 to 2025

KROS Stock  USD 11.29  0.16  1.40%   
Keros Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 3.4 M in 2025. Accounts Payable is the amount Keros Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Keros Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2019-12-31
Previous Quarter
M
Current Value
4.6 M
Quarterly Volatility
1.6 M
 
Covid
Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 285 K, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 159, Dividend Yield of 0.0 or PTB Ratio of 0.99. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Keros Therapeutics Correlation against competitors.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Latest Keros Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Keros Therapeutics over the last few years. An accounting item on the balance sheet that represents Keros Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Keros Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Keros Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Keros Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Keros Accounts Payable Regression Statistics

Arithmetic Mean1,825,227
Geometric Mean1,149,707
Coefficient Of Variation94.85
Mean Deviation1,489,755
Median501,000
Standard Deviation1,731,225
Sample Variance3T
Range4.9M
R-Value0.86
Mean Square Error848.2B
R-Squared0.74
Significance0.000021
Slope311,930
Total Sum of Squares45T

Keros Accounts Payable History

20253.4 M
20244.6 M
20235.5 M
20223.3 M
20213.6 M
20202.1 M
20192.1 M

About Keros Therapeutics Financial Statements

Keros Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable4.6 M3.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.